Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (University Medical Center Hamburg-Eppendorf/ University Medical Center Heidelberg).
Multiple Myeloma
DRUG: Revlimid (Lenalidomide)
Maximal tolerable dose of lenalidomide after allogeneic stem cell transplantation in patients with multiple myeloma, 2 years post-transplantation
Determination of remission status after lenalidomide treatment, 2 years post-transplantation|Effect on T-cell/ NK-cell recovery, 1 year post-transplantation|Incidence of infectious complications and GvHD, 1 year post-transplantation
This study is a Phase I (non-randomized) study evaluating three dose-levels of Lenalidomide in patients after allogeneic stem cell transplantation, accomplished in two institutions (University Medical Center Hamburg-Eppendorf/ University Medical Center Heidelberg).